O2h Ventures appeared to be the VC, which was created in 2003.
The usual things for fund are deals in the range of 1 - 5 millions dollars. Speaking about the real fund results, this VC is 51 percentage points more often commits exit comparing to other organizations. The high activity for fund was in 2019. The fund is constantly included in 2-6 investment rounds annually. Opposing the other organizations, this O2h Ventures works on 15 percentage points less the average amount of lead investments.
The typical case for the fund is to invest in rounds with 1-2 participants. Despite the O2h Ventures, startups are often financed by Innovate UK, Angel CoFund, Wellcome Trust. The meaningful sponsors for the fund in investment in the same round are Oxford Investment Opportunity Network, Esther Dyson, Delin Ventures. In the next rounds fund is usually obtained by Department of Health and Social Care (DHSC).
The fund was created by Sunil Shah.
The fund has no exact preference in some founders of portfolio startups. Among the most popular portfolio startups of the fund, we may highlight Oxford Drug Design, Exonate. Among the most popular fund investment industries, there are Software, SaaS. Besides, a startup requires to be at the age of 11-15 years to receive the investment from the fund.
|AGTech Holdings||China, Hong Kong, Hong Kong Island|
|CIT Healthcare Finance||-|
|Curious Office Partners||Seattle, United States, Washington|
|Digital Base Capital||Chiyoda, Japan|
|Enphase Energy||California, Petaluma, United States|
|Ernst & Young||England, London, United Kingdom|
|Hubei Dewo||China, Fujian, Hubei|
|JYTH||Beijing, Beijing, China|
|K-Svets Venture||Sweden, Vastra Gotaland, Västra Götaland County|
|Leonardo||Italy, Lazio, Roma|
|LINE Financial Corporation||Chiyoda, Japan|
|Matmut||France, Haute-Normandie, Rouen|
|Riverbed Technology||California, San Francisco, United States|
|Taaleri||Finland, Helsinki, Southern Finland|
|TDM Partners||China, Hong Kong, Hong Kong Island|
|Zhongshi Capital||China, Guangdong, Shenzhen|
|$1M||06 Jul 2022||Cambridge, Cambridgeshire, United Kingdom|
|$3M||14 Jun 2022||Cambridge, Cambridgeshire, United Kingdom|
Oxford Drug Design
|$3M||19 May 2022||Oxford, England, United Kingdom|
|$2M||28 Sep 2021||London, England, United Kingdom|
|$1M||08 Jul 2021||London, England, United Kingdom|
|$2M||20 Apr 2021||Cambridge, England, United Kingdom|
|$45M||23 Mar 2021||Cambridge, England, United Kingdom|
|22 Jan 2021||Cambridge, Cambridgeshire, United Kingdom|
|$6M||07 Jan 2021||Budapest, Hungary|
– Kuano.ai, a London, UK-based provider of a software platform for quantum modelling of enzymes, raised £1m in seed funding.
– Backers included ACF Investors, o2h Ventures and a syndicate of Cambridge-based angel investors.
– The company intends to use the funds to expand the technology team and further develop its platform and asset development, including its own range of novel therapeutics and creating a data bank for use in its work with academic and commercial partners.
– PhoreMost is a Cambridge, England, UK-based biopharmaceutical company.
– The company raised $46m in Series B funding.
– The round was led by BGF, and included new investor – XtalPi Inc., Astellas Venture Management, Trend Investment Group, and o2h ventures.
– Existing investors Parkwalk Advisors, Morningside Ventures, and Jonathan Milner also contributed.
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.